NUMA1 and urinary bladder carcinoma: The only currently commercially available test is NMP22 BladderChek, which is based on a POC solution using a chromatographic immunoassay for the qualitative detection of the nuclear matrix protein 22 (NMP22) protein, which is released by bladder cancer cells at higher levels than normal cells [58,59].